Cage Pharmaceuticals, Inc. — Form D
Cage Pharmaceuticals, Inc. of New York, NY, a company, filed a Form D exempt-offering notice with the SEC on 2024-05-31. The offering totals $137K, of which $137K was reported sold. Industry: Other Health Care.
Offering
- Filed: 2024-05-31
- Form: D
- Accession: 0001727073-24-000001
- Industry: Other Health Care
- Exemptions: 06b
- Total offering: $137K
- Amount sold: $137K
- Investors: 2
- Date of first sale: 2024-05-01
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-514783
Issuer
- Name: Cage Pharmaceuticals, Inc.
- CIK: 0001727073
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: 512 W. 22nd Street, New York, NY, 10011
- Phone: 917-832-1832
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| Brian Malik | Director | New York, NY |
| Peter Olagunju | Director | Houston, TX |
| Nick Papadopoulos | Director | New York, NY |
| Isaac Ro | Director | San Mateo, CA |
| Peter Olagunju | Executive Officer | Houston, TX |
| Jason Rifkin | Executive Officer | New York, NY |
Other filings by this issuer (2)
More